Researchers at the
DTCs are circulating tumour cells (CTCs) that have left the primary tumour and travelled in the blood to a distant organ, in this instance bone marrow, where they can remain dormant before being released at a later date. Release of these cells into the blood, is thought to be the most likely cause of relapse for patients who have had a prolonged remission.
One-third of breast cancer patients have DTCs already present in the bone marrow at the time of diagnosis; these patients, as well as patients with persistent DTCs, have significantly worse clinical outcomes than DTC-negative patients. Since DTC biomarker status may differ from the primary tumour with regard to key proliferation and growth receptors such as ER and HER2, the ability to evaluate these markers on DTCs may enable clinicians to optimise targeted therapy and reduce the risk of relapse.
ANGLE Chief Scientific Officer,
The research has been published as a peer-reviewed publication in the
Contact:
Tel: +44 (0) 1483 343434
About
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the
Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system.
(C) 2023 Electronic News Publishing, source